GSK-3 β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma.
In conclusion and to the best of our knowledge, the current study was the first to determine that GSK-3β is a target gene of HNF-1β. In addition, the results of the present study revealed the novel HNF-1β-GSK-3β-p-NFκB pathway, occurring in response to DNA damage. Targeting this pathway may therefore represent a putative, novel, anticancer strategy in patients with OCCC.
PMID: 33005248 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Cancer & Oncology | Carcinoma | Clear Cell Carcinoma | General Medicine | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study | Urology & Nephrology